Back to top
more

Amneal Pharmaceuticals (AMRX)

(Delayed Data from NSDQ)

$7.45 USD

7.45
673,631

+0.21 (2.90%)

Updated Jul 22, 2024 04:00 PM ET

After-Market: $7.45 0.00 (0.00%) 7:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (146 out of 250)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Amneal (AMRX) Shares Down on CRL for Parkinson's Disease Drug

Amneal (AMRX) suffers a setback as the FDA issues a complete response letter (CRL) to its new drug application (NDA) for IPX203 for treating Parkinson's disease.

Earnings Preview: Theravance Biopharma (TBPH) Q1 Earnings Expected to Decline

Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Amneal Pharmaceuticals (AMRX) to Report a Decline in Earnings: What to Look Out for

Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amneal Pharmaceuticals (AMRX) Beats Q4 Earnings and Revenue Estimates

Amneal (AMRX) delivered earnings and revenue surprises of 9.52% and 4.91%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

FDA Accepts Amneal's (AMRX) Parkinson's Candidate NDA For Review

Amneal Pharmaceuticals' (AMRX) shares rise after the company announces that its Parkinson's candidate IPX203 NDA has been accepted for review by the FDA.

Amneal Pharmaceuticals (AMRX) Q3 Earnings and Revenues Lag Estimates

Amneal (AMRX) delivered earnings and revenue surprises of -22.22% and 3.37%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Select Medical (SEM) Q3 Earnings Miss Estimates

Select Medical (SEM) delivered earnings and revenue surprises of -52.27% and 1.14%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Implied Volatility Surging for Amneal Pharmaceuticals (AMRX) Stock Options

Investors need to pay close attention to Amneal Pharmaceuticals (AMRX) stock based on the movements in the options market lately.

Amneal Pharmaceuticals (AMRX) Lags Q2 Earnings Estimates

Amneal (AMRX) delivered earnings and revenue surprises of -5% and 4.63%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Amneal Pharmaceuticals (AMRX) Q1 Earnings Meet Estimates

Amneal (AMRX) delivered earnings and revenue surprises of 0% and 0.61%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Amneal Pharmaceuticals (AMRX) Lags Q4 Earnings Estimates

Amneal (AMRX) delivered earnings and revenue surprises of -5.26% and 1.28%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?

Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year?

Here is how Amneal Pharmaceuticals (AMRX) and Athersys, Inc. (ATHX) have performed compared to their sector so far this year.

Is Amneal Pharmaceuticals (AMRX) a Suitable Pick for Value Investors?

Is Amneal Pharmaceuticals (AMRX) a great pick from the value investor's perspective right now? Read on to know more.

Amneal Pharmaceuticals (AMRX) Tops Q3 Earnings Estimates

Amneal (AMRX) delivered earnings and revenue surprises of 5.00% and -3.27%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Amneal Pharmaceuticals (AMRX) to Report Q3 Results: Wall Street Expects Earnings Growth

Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why the Earnings Surprise Streak Could Continue for Amneal (AMRX)

Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Amneal (AMRX) Parkinson's Candidate Successful in Pivotal Study

Amneal's (AMRX) IPX-203 increases "Good On" time by 1.55 hours per dose versus immediate-release CD/LD in patients with Parkinson's disease.

Amneal Pharmaceuticals (AMRX) Q2 Earnings and Revenues Top Estimates

Amneal (AMRX) delivered earnings and revenue surprises of 38.89% and 1.86%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AMRX vs. ZTS: Which Stock Should Value Investors Buy Now?

AMRX vs. ZTS: Which Stock Is the Better Value Option?

AMRX or ZTS: Which Is the Better Value Stock Right Now?

AMRX vs. ZTS: Which Stock Is the Better Value Option?

Amneal Pharmaceuticals (AMRX) Q1 Earnings Beat Estimates

Amneal (AMRX) delivered earnings and revenue surprises of 11.11% and -2.81%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Amneal Pharmaceuticals (AMRX) Q1 Earnings Expected to Decline

Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amneal Pharmaceuticals (AMRX) Surpasses Q4 Earnings and Revenue Estimates

Amneal (AMRX) delivered earnings and revenue surprises of 7.69% and 1.55%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?